基于Tragacanth乳糖深度浸泡溶剂的浸泡溶剂,用于通过皮肤输送德克斯特罗梅索芬和诱导性类风湿性关节炎治疗大鼠
Atefe Fatahi1, Jaleh Varshosaz1, Valiollah Hajhashemi2
1Department of Pharmaceutics, Faculty of Pharmacy and Novel Drug Delivery Systems Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
International journal of biological macromolecules
|July 31, 2025
概括
一种新型的eutectogel增强了德克斯特罗梅索芬 (DXM) 的溶解性和类风湿性关节炎的通过皮肤传递. 这种基于巴索林的凝显示出改善的皮肤透性和与口服甲索特酸相比的抗炎作用.
科学领域:
- 材料科学 材料科学 材料科学
- 制药科学 制药科学
- 生物技术是生物技术.
背景情况:
- 类风湿性关节炎 (RA) 对有效的药物治疗构成了重大挑战.
- 开发新的药物输送系统对于改善RA治疗治疗结果至关重要.
- 自然的大分子为制药配方提供具有生物相容性平台的潜力.
研究的目的:
- 开发一种新型的eutectogel,用于通过皮肤输送德克斯甲 (DXM).
- 为了研究从特拉加坎特中获得的巴索林 (Ba) 的潜力,作为深溶剂的凝剂.
- 在类风湿性关节炎的动物模型中评估开发的eutectogel的疗效.
主要方法:
- 使用巴索林 (Ba),胆化物 (ChCl),酸和水,制备欧特基凝.
- 优特基凝的表征,包括溶解性研究,学分析和纹理特征分析.
- 在实验室使用老鼠皮肤进行皮肤透研究.
- 在风湿性关节炎的老鼠模型中进行体内抗炎功效的评估.
主要成果:
- 化和酸的性混合物提高了DXM的可溶性超过1700倍.
- 欧特基凝表现出高达80°C的理想凝一致性和优越的结构完整性.
- 与单独使用巴索林凝相比,含水量为20%的eutectogels显著增加了DXM皮肤流量.
- 在体内研究显示,足部胀和TNF-α水平的降低与口服甲状腺素相似,膝关节关节组织结构几乎正常.
结论:
- 一种基于bassorin的新型eutectogel有效地提供了德克斯特罗米多芬,用于透皮应用.
- 开发的eutectogel系统显示出在治疗类风湿性关节炎症状方面具有显著的潜力.
- 这种方法为治疗RA的传统口服药物管理提供了一个有希望的替代方案.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...